← Leaderboards
Brian C Gilger
Bedrock Therapeutics, Inc.
$1,329,210
Attributed
$2,658,419
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2020–25$2M$1.5M$1M$500K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,658,419 · 4
By mechanism
R42$1,769,317 · 1
R41$889,102 · 3
Top collaborators
- Matthew Louis Hirsch6 shared
Others in their field
Other Emerging Leaders on “Dose”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$124,321,134
- Beth Baseler · Leidos Biomedical Research, Inc.$52,807,683
- Susan Abushakra · Alzheon, Inc.$47,265,244
- Paula Gonzalez-Maya · Fundacion Inciensa$37,578,679
- Xinhua Li · Nano Terra, Inc.$35,520,438
- Jeffrey Reich · Sparian Biosciences, Inc.$28,575,028
Research focus
DoseImmuneCorneaImmunoregulationVectorDependovirusPreventionPreventProductionOryctolagus CuniculusImmune ResponseVascularizationAllogenicGraft RejectionQuality Of LifeImmunosuppressive AgentsKeratoplastyBlindnessHigh RiskTransplantationEconomic ImpactEngineeringAnimal ModelAdeno-Associated Viral Vector
Grant awards (6)
Prevention of corneal transplant rejection using AAV-BDRK-401 therapy$793,930
R42 · FY2025 · EY · contact PI
Vector mediated anti-vascular and anti-inflammatory therapy for AMD$310,952
R41 · FY2025 · EY · contact PI
Prevention of corneal transplant rejection using AAV-BDRK-401 therapy$975,387
R42 · FY2024 · EY · contact PI
Immunosuppressive Gene Therapy for Ocular Graft vs Host Disease$328,150
R41 · FY2021 · EY · contact PI
Prevention of corneal transplant rejection using AAV-HLA-G combination therapy$171,923
R41 · FY2021 · EY · contact PI
Prevention of corneal transplant rejection using AAV-HLA-G combination therapy$78,077
R41 · FY2020 · EY · contact PI